Aravax forms research collaboration with Stanford University

17th November 2017 – Aravax today signed a collaborative agreement with Stanford University in California. The Stanford research group, led by Professor Kari Nadeau, will collaborate with Aravax to further explore the immunological responses to Aravax's revolutionary peanut allergy therapy, PVX108**.** Professor Kari Nadeau is one of the foremost experts in adult and pediatric allergy and asthma and is the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. As part of the collaborative agreement, Professor Kari Nadeau's group will receive clinical samples from Aravax's ongoing clinical trial, AVX001.

PVX108 utilises peptides that represent carefully selected fragments of peanut proteins to switch off allergic reactions to peanuts. Unlike other peanut allergy immunotherapies under development, the peptides do not contain the parts of the peanut proteins that cause life-threatening anaphylactic reactions. This collaboration now involves Aravax, Stanford University and the Benaroya Research Institute and will enable further testing of PVX108 used in our clinical trial, which is expected to be completed the second half of 2018.

Pascal Hickey, CEO of Aravax said *"Aravax is proud to expand our collaborative efforts and announce the addition of Stanford University to the ongoing research we are conducting with the Benaroya Research Institute. We look forward to the completion of our phase 1 trials."*

Ends

Media enquiries:

Aravax & MRCF: Andrew Hamilton +61420 447 669 or ah@manacommunications.com

About the Clinical Trial AVX-001

The clinical research centers are currently seeking peanut-allergic individuals to participate in the trial. If you are 18-65 years of age and interested in participating, please contact one of the clinical trial centers:

CMAX, Adelaide – 1800 150 433

Nucleus Network, Melbourne – 03 8593 9875

About Aravax

Aravax is a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The treatment will use highly targeted technology that can reset the immune system to tolerate peanut without evoking allergic reactions during treatment.

Aravax's technology is underpinned by over a decade of research led by Professor Robyn O'Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council.

The novel technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. These fragments do not contain the parts of the nut proteins that cause the life-threatening anaphylactic reactions that can make other proposed peanut allergy therapeutics unsafe.

Aravax is headquartered in Melbourne, Australia.

For more information visit: www.aravax.com.au

About the Australian Medical Research Commercialisation Fund (MRCF)

The MRCF collaboration is managed by the venture capital firm Brandon Capital Partners, and provides seed and venture capital investment to support the development and growth of Australian life science companies.

Established in late 2007, the MRCF is a unique collaboration between major Australian superannuation funds, over 50 leading medical research institutes and research hospitals in Australia and New Zealand. The MRCF supports the development and commercialisation of very early-stage biomedical discoveries originating from these member research organisations, providing both capital and expertise to guide the successful development of new therapies. The MRCF acknowledges the support of the Australian and New Zealand governments, as well as the state governments of Victoria, New South Wales, Western Australia, Queensland, South Australia and the Australian Capital Territory.

For more information visit: www.mrcf.com.au

Aravax Pty Ltd

Level 9, 31 Queen Street, Melbourne VIC 3000 Australia

Office +61 3 9657 0700 I Fax +61 3 9657 0777